Publication
2nd Circuit defers to executive will on application of sovereign immunity
The Second Circuit recently held that federal common law protections of sovereign immunity did not preclude prosecution of a state-owned foreign corporation.
United States | Publication | October 2022
The corporate opportunity doctrine precludes fiduciaries from “divert[ing] and exploit[ing] for their own benefit any opportunity that should be deemed an asset of the corporation.” O’Mahony v. Whiston, No. 652621/2014, 2019 WL 4899030, at *6 (N.Y. Co. Oct. 4, 2019) (citing Alexander & Alexander of N.Y., Inc. v. Fritzen, 147 A.D.2d 241, 246 (1st Dep’t 1989)).
The doctrine is premised on the notion that a corporate officer or director may not personally profit at the expense of the corporation. See Troffa v. Troffa, No. 6095102016, 2022 WL 3140457, at *6 (Suffolk Co. Aug. 2, 2022). When a fiduciary usurps or diverts a corporate opportunity, “he may be held accountable for the fruits of his wrongdoing.” Sheiffer v. Petry Holding, No. 601792/2004, 2005 WL 6578258 (N.Y. Co. 2005).
New York courts generally use two non-exclusive tests to determine whether the opportunity at issue was a corporate opportunity: (1) the tangible expectancy test and (2) the line of business test. While these tests help assess what constitutes a “corporate opportunity,” some courts take a more general approach assessing all relevant factors.
Read the full New York Law Journal article, "Usurpation of corporate opportunities."
Publication
The Second Circuit recently held that federal common law protections of sovereign immunity did not preclude prosecution of a state-owned foreign corporation.
Publication
Facing the fast-growing development of AI across the globe, particularly Generative AI (GenAI), the G7 competition authorities and policymakers (Canada, France, Germany, Japan, Italy, the UK and the US) and the European Commission met in Italy on 3-4 October 2024 to discuss the main competition challenges raised by these new technologies in digital markets.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023